739 related articles for article (PubMed ID: 26857292)
1. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
2. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
3. Evolution of prodromal parkinsonian features in a cohort of
Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
[TBL] [Abstract][Full Text] [Related]
4. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
5. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
6. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
[TBL] [Abstract][Full Text] [Related]
7. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
9. A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
den Heijer JM; Cullen VC; Pereira DR; Yavuz Y; de Kam ML; Grievink HW; Moerland M; Leymarie N; Khatri K; Sollomoni I; Spitalny L; Dungeon L; Hilt DC; Justman C; Lansbury P; Groeneveld GJ
Mov Disord; 2023 May; 38(5):783-795. PubMed ID: 36916660
[TBL] [Abstract][Full Text] [Related]
10. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
11. β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease.
Moraitou M; Hadjigeorgiou G; Monopolis I; Dardiotis E; Bozi M; Vassilatis D; Vilageliu L; Grinberg D; Xiromerisiou G; Stefanis L; Michelakakis H
Mol Genet Metab; 2011; 104(1-2):149-52. PubMed ID: 21745757
[TBL] [Abstract][Full Text] [Related]
12. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
13. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
[TBL] [Abstract][Full Text] [Related]
14. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
[TBL] [Abstract][Full Text] [Related]
15. Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort.
Crosiers D; Verstraeten A; Wauters E; Engelborghs S; Peeters K; Mattheijssens M; De Deyn PP; Theuns J; Van Broeckhoven C; Cras P
Neurosci Lett; 2016 Aug; 629():160-164. PubMed ID: 27397011
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients.
Alcalay RN; Wolf P; Chiang MSR; Helesicova K; Zhang XK; Merchant K; Hutten SJ; Scherzer C; Caspell-Garcia C; Blauwendraat C; Foroud T; Nudelman K; Gan-Or Z; Simuni T; Chahine LM; Levy O; Zheng D; Li G; Sardi SP;
Ann Clin Transl Neurol; 2020 Oct; 7(10):1816-1830. PubMed ID: 32888397
[TBL] [Abstract][Full Text] [Related]
18. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
[TBL] [Abstract][Full Text] [Related]
19. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
Beavan MS; Schapira AH
Ann Med; 2013 Dec; 45(8):511-21. PubMed ID: 24219755
[TBL] [Abstract][Full Text] [Related]
20. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
